ESSA Pharma Inc Logo
CA29668H7085
EPIX

ESSA Pharma Inc

Prévisions

L'objectif de cours moyen des analystes est de 8,66 € (+368,11 %). La médiane est de 8,66 € (+368,11 %).

Acheter
  2
Conserver
  3
Vendre
  0

Discussions dans la communauté

Il n'y a pas encore de discussion sur cet actif.

Lancer une discussion

  • XenoTherapeutics completes acquisition of ESSA Pharma

    XenoTherapeutics has completed the acquisition of ESSA Pharma and acquired all outstanding common shares through its subsidiary Xeno Acquisition Corp. for about $0.1242 per share. The previously revised terms were supplemented by a contingent value right (CVR) that can enable additional payments of up to $0.14 per share and up to $6.7 million in total. The acquisition was approved by the Supreme Court of British Columbia; ESSA has applied to delist from Nasdaq and plans an $80 million liquidation distribution to shareholders. » Plus sur de.investing.com


  • ESSA Pharma shareholders approve takeover by XenoTherapeutics

    Holders of ESSA Pharma securities voted by an overwhelming majority (99.83% and 99.85% including options/warrants) to approve the takeover by XenoTherapeutics under a plan of arrangement. The transaction remains subject to court approval by the Supreme Court of British Columbia; the hearing is scheduled for October 7, 2025, and closing is expected around October 9, 2025. ESSA announced amended deal terms: the expected cash payment was reduced from 1.91 USD to about 0.12 USD per share, and shareholders will also receive a non-transferable CVR with a possible payment of up to 0.14 USD; additionally, an $80 million distribution to shareholders is planned. Shareholders also provisionally approved a voluntary liquidation in case the takeover fails and voted to approve the transaction-related compensation for executives. » Plus sur de.investing.com


  • ESSA Pharma gets court approval for meeting date for takeover by XenoTherapeutics

    The Supreme Court of British Columbia approved the rescheduling of ESSA Pharma’s extraordinary general meeting to Oct. 3, 2025 as an online webcast; stakeholders can object until Oct. 1, and court approval of the deal is set for Oct. 7. XenoTherapeutics is to acquire all issued common shares of ESSA, but the merger terms were revised: the expected cash payout was cut from about $1.91 to roughly $0.12 per share and a non‑transferable CVR worth up to $0.14 was added. ESSA plans an $80m distribution to shareholders (payment date Aug. 22) and the acquisition financing comes from XOMA Royalty Corporation. The micro‑cap stock is trading near its 52‑week low and is down 74% year to date. » Plus sur de.investing.com


  • ESSA Pharma: changed merger terms drastically cut payout forecast, stock falls 17%

    ESSA Pharma adjusted the terms of the merger with XenoTherapeutics, reducing the expected per-share payout from about $1.91 to roughly $0.12. Additionally, contingent value rights of up to $0.14 per share are to be issued, with payouts tied to specific events. The company cites updated cash estimates and potential liabilities as reasons; XOMA Royalty remains structuring agent and intends to finance the transaction. The stock fell 17% in premarket trading. ESSA postponed the special shareholder meeting to October 3 and will report the change in a Form 8‑K. » Plus sur de.investing.com


  • ESSA Pharma cuts payouts in amended merger agreement with XenoTherapeutics

    ESSA Pharma has amended the terms of its takeover by XenoTherapeutics, reducing the cash payment at closing from about $1.91 to roughly $0.12 per share. In addition, shareholders will receive one non-transferable CVR per share with a potential additional payout of up to about $0.14 per CVR. The company cites potential liabilities, related costs and current cash balance forecasts as reasons; the extraordinary general meeting has been postponed to October 3. XOMA Royalty Corporation remains structuring adviser and financier of the transaction; InvestingPro considers ESSA undervalued at its current market capitalization. » Plus sur de.investing.com

En 2025, ESSA Pharma Inc a déjà versé 1,44 € de dividendes. Le dernier versement a eu lieu en août 2025.

Données financières

Au dernier trimestre, ESSA Pharma Inc a réalisé un chiffre d'affaires de 0 € et un bénéfice net de -3,4 M €

(EUR) juin 2025
YoY
Chiffre d'affaires 0 -
Bénéfice brut -13,9 k -
Bénéfice net -3,4 M -
EBITDA -4,22 M -

Données fondamentales

Indicateur Valeur
Capitalisation boursière
8,67 M €
Nombre d'actions
47,31 M
Plus haut/bas sur 52 semaines
5,88 € - 0,16 €
Dividendes Non
Bêta
1,53
Ratio P/E
-0,31
Ratio PEG
-0,04
Ratio P/B
0,07
Ratio P/S
0,00

Profil de l'entreprise

ESSA Pharma Inc., une société pharmaceutique au stade clinique, se concentre sur le développement de thérapies novatrices et exclusives pour le traitement du cancer de la prostate. Elle développe l'EPI-7386, un candidat par voie orale actuellement en étude clinique de phase I pour le traitement de patients atteints d'un cancer de la prostate métastatique résistant à la castration. La société a conclu des accords de collaboration avec Caris Life Sciences, Inc. ; Bayer Consumer Care AG ; Janssen Research & Development, LLC ; et Astellas Pharma Inc. ESSA Pharma Inc. a été constituée en 2009 et its siège social se trouve à Vancouver, au Canada.

Nom
ESSA Pharma Inc
PDG
David Ross Parkinson
Siège social Vancouver, bc
Canada
Site web
Secteur
Matériaux
Industrie
Produits chimiques
Introduction en bourse
13/03/2015
Employés 35

Symboles boursiers

Bourse Symbole
NASDAQ
EPIX
🍪

Parqet  utilise des cookies. En savoir plus